Funding
1 min read
Deep Intelligent Pharma has secured nearly US$50 million in Series D funding to revolutionize clinic...
The AMW Read
This updates the player map for the Healthcare/Bio vertical with a significant Series D round for a multi-agent clinical research platform, though it does not trigger cross.§D as the amount is under $500M.
NoveltySignificance
Healthcare & Bio · Player Map
Deep Intelligent Pharma has secured nearly US$50 million in Series D funding to revolutionize clinical trials with its multi-agent AI platform. This investment will accelerate the development of an AI-native clinical research system, streamlining thousands of atomic tasks in drug development. Moving to a milestone-based value pricing model, DIP’s secure platform, serving over 1,000 pharmaceutical companies and 40,000 projects, promises to significantly enhance R&D efficiency and foster innovation.
#AI #ClinicalTrials #Pharma #DrugDevelopment #Innovation
